What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

Evaluate sustained minimal residual disease (sMRD) negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients.

December 8, 2025Blood

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

View Full Paper

Ask AI

Bookmark

Authors

SMSalomon ManierCentre National de la Recherche Scientifique APAurore PerrotCentre Hospitalier Universitaire de Toulouse NBNoémie BigotInserm

Discussion

Member takes

Implication

Phase 3 trial shows improved sustained MRD negativity in transplant-ineligible patients with newly diagnosed multiple myeloma, suggesting Isa-VRd may lower disease burden.

Key Points

Evaluate sustained minimal residual disease (sMRD) negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients.
Multicenter, phase 3 randomized trial comparing Isa-VRd vs Isa-Rd
Assessment of MRD negativity at 12-24 months
Involvement of NDMM transplant-ineligible patients
At 24 months, sustained MRD negativity at 10⁻⁵ was significantly higher in the Isa-VRd arm (OR 2.73)
Median follow-up of 33.4 months
No new safety signals observed in treatment arms including high-risk patients

Cite This Study

Manier et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e096 https://doi.org/10.1182/blood-2025-368

View Full Paper

Ask AI

Bookmark

Implication

Phase 3 trial shows improved sustained MRD negativity in transplant-ineligible patients with newly diagnosed multiple myeloma, suggesting Isa-VRd may lower disease burden.

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Discussion

Member takes

Implication

Key Points

Cite This Study

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider